Alzheimer's disease is a large and ...

Alzheimer's disease is a large and increasing public health vexed question Because the cognitive deficits of the disease are idea to result from degeneration of cholinergic basal fore-brain neuron therapy with cholinesterase inhibitors was bring outed to raise acetylcholine levels in the brain. Randomized controll trials of three to 12 month of therapy in preferableed patients with mild to moderate Alzheimer's disease have demonstrated small improvements in cognitive function. However, the powers on behavior and function have been inconsistent, and long-term benefits and results on quality of life have not been established. The AD2000 Collaborative cluster undertook a large multicenter trial of the long-term benefits of donepezil in Alzheimer's disease.

The meditation included more than 500 patients referr to a memory clinic in the West Mid-lands region of England. All patients met the Diagnostic and Statistical Manual of Mental Disorders, 4th ed criteria for Alzheimer's-related dementia, lived in the community, had a regular caretaker and no contraindications to donepezil, and were not already taking a cholinesterase inhibitor. During the initial 12 weeks of the thought 282 patients were randomly assigned to 5 mg donepezil by day, and 283 received an identical placebo. Of the 511 patients who complet this phase, 486 were re-randomized to receive 5 or 10 mg of donepezil daily (242 patients) or placebo (244 patients). After 48 weeks of treatment, all patients had a six-week washout phase during which no active anti-Alzheimer's therapy was given. Patients were then exempt to continue their previous therapy for another 48 weeks. After a further four-week washout period, united more 48-week treatment period was tendered During the study, all other treatments were continued at the discretion of the patient's usual physician. The primary end-points were admission to institutional care and changes in scores forward the Bristol Activities of Daily Living Scale (BADLS) of functional activity. Other issues included behavioral and psychologic symptoms or signs of dementia, cognitive function (as measured on the Mini-Mental State Examination [MMSE]) psychologic well-being of the principal care-giver, death attributed to Alzheimer's disease, adverse tenors of therapy, and compliance with therapy. The investigation also included an economic evaluation to ascertain the cost-effectiveness of donepezil therapy.

The treatment clusters remained well balanced throughout the subject of attention in terms of comorbidities, severity of dementia, medications, and other relevant variables. During the run-in period, significantly more patients allocated to donepezil dropp gone out compared with the control assemblage (30 compared with 13). Three of the placebo and 17 of the donepezil patients attributed discontinuation to side powers This trend continued after 13 weeks, with 7 percent of the donepezil assemblage and 3 percent of the placebo arrange withdrawing from the study because of side effects

The rates of institutionalization and progression of disability at common and three years were not significantly different in the treatment and placebo collections and no significant differences could be finded in behavioral and psychologic symptoms. throughout the first two years, treated patients scored an average of single in kind point higher than control patients forward the BADLS and 0.8 points higher upon the MMSE, but the clinical significance of these differences is unclear, especially because of the greater dropout rate in the donepezil arrange Serious adverse events were descryed in 29 patients taking donepezil and 23 taking placebo. The number of deaths and the proportion of deaths attributed to dementia were comparable in the couple groups. No significant differences were find outed between the groups in caregiver psychopathology or health care costs

The authors finish that the small improvements in cognition and function discovered over two years were not cogitateed in rates of institutionalization, disability, or benefits to caregivers. Donepezil was not a cost-effective therapy for Alzheimer's dementia.

AD2000 Collaborative dispose Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomised double-blind trial. Lancet June 26 2004;363:2105-15

EDITOR'S NOTE: to what degree could the results of this research influence care of older patients with Alzheimer's disease and the advice physicians give to families? The task is to provide objective information and guidance without destroying reliance This study appears to contradict several previous studies and meta-analyses that indicated improvement in function and delay in institutionalization with cholinesterase-inhibitor therapy. (12) Careful reading reveals that almost all published studies indicate small improvements (or delay in deterioration) in results despite differences in patient selection, investigation design, and outcome measures. The altercation concerns the implications of these benefits--do they make meaningful differences for patients and are they worth the human and financial costs? Particular care is emergencyed in applying this British application of mind to U.S. patients. The factors influencing the decision to institutionalize may be different between the couple countries because of significant differences in health care schemes availability of community services, and societal expectations of the appropriate care of parts with dementia. All studies agree that there is a ne for effective, safe, acceptable, and affordable therapies for dementing illnesses.